Anthony Lucci

20.9k total citations · 2 hit papers
254 papers, 11.3k citations indexed

About

Anthony Lucci is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Anthony Lucci has authored 254 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Oncology, 145 papers in Cancer Research and 54 papers in Pathology and Forensic Medicine. Recurrent topics in Anthony Lucci's work include Breast Cancer Treatment Studies (109 papers), Cancer Cells and Metastasis (64 papers) and Breast Lesions and Carcinomas (48 papers). Anthony Lucci is often cited by papers focused on Breast Cancer Treatment Studies (109 papers), Cancer Cells and Metastasis (64 papers) and Breast Lesions and Carcinomas (48 papers). Anthony Lucci collaborates with scholars based in United States, France and United Kingdom. Anthony Lucci's co-authors include Kelly K. Hunt, Balraj Singh, Henry M. Kuerer, Savitri Krishnamurthy, Armando E. Giuliano, Massimo Cristofanilli, Carolyn Hall, Naoto T. Ueno, Wendy A. Woodward and Funda Meric‐Bernstam and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Anthony Lucci

246 papers receiving 11.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis

2014 1.3k citations Anthony Lucci et al. profile →
Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011

2007 660 citations Anthony Lucci, Kelly K. Hunt et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Anthony Lucci	6.1k	5.5k	3.2k	2.4k	2.3k	254	11.3k
David W. Ollila	4.3k 0.7×	4.6k 0.8×	1.7k 0.5×	1.8k 0.7×	2.3k 1.0×	173	8.1k
Roman Rouzier	6.0k 1.0×	5.6k 1.0×	2.5k 0.8×	3.7k 1.5×	2.8k 1.2×	484	16.8k
Randall E. Brand	2.4k 0.4×	5.6k 1.0×	3.2k 1.0×	2.8k 1.2×	1.9k 0.8×	253	9.8k
Tari A. King	5.6k 0.9×	3.9k 0.7×	1.7k 0.5×	2.1k 0.9×	3.0k 1.3×	288	9.4k
Michael S. Sabel	2.7k 0.4×	3.8k 0.7×	3.0k 0.9×	1.5k 0.6×	1.4k 0.6×	174	8.8k
Gary M. Tse	3.4k 0.6×	3.6k 0.7×	2.4k 0.8×	1.8k 0.8×	3.5k 1.5×	324	11.4k
Isabelle Bedrosian	5.8k 1.0×	4.0k 0.7×	1.3k 0.4×	2.7k 1.1×	3.5k 1.5×	238	9.3k
Harry D. Bear	6.4k 1.0×	6.6k 1.2×	1.5k 0.4×	1.8k 0.7×	3.5k 1.5×	173	11.5k
Peggy L. Porter	3.9k 0.6×	7.5k 1.4×	4.1k 1.3×	1.5k 0.6×	1.5k 0.6×	140	13.3k
David G. Mutch	2.9k 0.5×	4.3k 0.8×	4.0k 1.2×	4.6k 1.9×	2.7k 1.2×	449	19.1k

Countries citing papers authored by Anthony Lucci

Since Specialization

Citations

This map shows the geographic impact of Anthony Lucci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Lucci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Lucci more than expected).

Fields of papers citing papers by Anthony Lucci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Lucci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Lucci. The network helps show where Anthony Lucci may publish in the future.

Co-authorship network of co-authors of Anthony Lucci

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Lucci. A scholar is included among the top collaborators of Anthony Lucci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Lucci. Anthony Lucci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tarantino, Paolo, Antonio Giordano, Faina Nakhlis, et al.. (2024). Abstract PO3-20-06: TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer. Cancer Research. 84(9_Supplement). PO3–20. 2 indexed citations

Kuerer, Henry M., Gaiane M. Rauch, Savitri Krishnamurthy, et al.. (2023). 243MO Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial. Annals of Oncology. 34. S280–S280. 1 indexed citations

Asare, Elliot A., Sarah B. Fisher, Yi‐Ju Chiang, et al.. (2023). Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. Journal of Surgical Oncology. 128(2). 313–321. 5 indexed citations

Singh, Balraj, et al.. (2023). Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer. Cancers. 15(7). 2036–2036. 3 indexed citations

Lucci, Anthony, Sridevi Addanki, Yi‐Ju Chiang, et al.. (2023). Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma. Cancers. 15(14). 3630–3630. 3 indexed citations

Burton, Elizabeth M., Lauren Simpson, Víctor G. Prieto, et al.. (2023). Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9583–9583. 1 indexed citations

Singh, Balraj, et al.. (2022). Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor. Cancers. 14(11). 2631–2631. 2 indexed citations

Addanki, Sridevi, et al.. (2022). Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. International Journal of Molecular Sciences. 23(14). 7843–7843. 28 indexed citations

Wang, Yuling, Vijaya Ramachandran, Dawen Sui, et al.. (2021). Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. Journal of Investigative Dermatology. 142(7). 2046–2049.e3. 16 indexed citations

10.

Lucci, Anthony, Carolyn Hall, Sapna P. Patel, et al.. (2020). Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research. 26(8). 1886–1895. 52 indexed citations

11.

Singh, Puneet, et al.. (2020). Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score. Breast Cancer Research and Treatment. 184(3). 683–687. 3 indexed citations

12.

Kida, Kumiko, Kenneth R. Hess, Bora Lim, et al.. (2020). Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers. 12(11). 3105–3105. 1 indexed citations

13.

Postlewait, Lauren M., Mediget Teshome, Sarah M. DeSnyder, et al.. (2020). Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Annals of Surgical Oncology. 27(12). 4603–4612. 12 indexed citations

14.

Fayanju, Oluwadamilola M., Carolyn Hall, Jessica B. Bauldry, et al.. (2017). Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. The American Journal of Surgery. 214(4). 666–671. 7 indexed citations

15.

Janni, Wolfgang, Brigitte Rack, Leon W.M.M. Terstappen, et al.. (2016). Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clinical Cancer Research. 22(10). 2583–2593. 265 indexed citations

16.

Roland, Christina L., et al.. (2015). Detection of circulating melanoma cells in the blood of melanoma patients. Melanoma Research. 25(4). 335–341. 19 indexed citations

17.

Dawood, Shaheenah, Sofía D. Merajver, Patrice Viens, et al.. (2010). International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology. 22(3). 515–523. 331 indexed citations

18.

Zhang, Dongwei, Tiffany A. LaFortune, Savitri Krishnamurthy, et al.. (2009). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clinical Cancer Research. 15(21). 6639–6648. 98 indexed citations

19.

Cook, Kendra R., Balraj Singh, Laura Vincent, et al.. (2008). 41. Cyclooxygenase-2 Induces Genomic Instability, BCL2 Expression, Doxorubicin Resistance, and Altered Cancer Initiating Cell Phenotype in MCF7 Breast Cancer Cells. Journal of Surgical Research. 144(2). 193–194. 3 indexed citations

20.

Gonzalez, Ricardo J., Aman U. Buzdar, W. Fraser Symmans, et al.. (2007). Novel Clinical Trial Designs for Treatment of Ductal Carcinoma In Situ of the Breast with Trastuzumab (Herceptin). The Breast Journal. 13(1). 72–75. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact